Melissa didn’t take a multi-cancer early detection (MCED) test once and leave it at that. She made MCED testing part of her annual health routine. The first year, the test did not detect a cancer signal. The second year, she received a Cancer Signal Detected result with a predicted origin of liver/bile ducts. Melissa felt healthy and had no symptoms. Follow up diagnostic testing confirmed Stage I bile duct cancer. Now she’s using her story to encourage others to keep cancer screening part of the conversation, year after year. #CancerScreening #EarlyCancerDetection #MCED The overall sensitivity in study participants with liver/bile duct cancer was 93.5% (100% for stage I, 70.0% stage II, 100% stage III, 100% stage IV). Rx only. See Important Safety Information: galleri.com/safety-informati…

“Early detection can save an awful lot of lives, I think I’m evidence of that.” Ann joined the NHS-Galleri trial evaluating a multi-cancer early detection (MCED) test hoping her participation might help others. She never imagined it would help her, too. Watch her story and learn more about the NHS-Galleri trial: bit.ly/4wY05Ij The overall sensitivity in study participants with colon/rectum cancer was 82% (43.3% for stage I, 85% stage II, 87.9% stage III, 95.3% stage IV).

Robert signed on for the NHS-Galleri trial with the intention of advancing cancer research. When the multi-cancer early detection (MCED) test returned a Cancer Signal Detected result, he was shocked. On the latest episode of The Cancer SIGNAL podcast, host Rayshawnda Madison speaks with Robert as he shares how his follow-up journey eventually led to an early HPV-related cancer diagnosis, what it was like to navigate treatment and recovery, and how the experience changed the way he thinks about health and early detection. The Cancer SIGNAL is available wherever you listen to podcasts. #EarlyCancerDetection #MCED #Podcast Apple Podcasts: bit.ly/4byN5jM Spotify: bit.ly/4bOp9I4 Transcripts & more episodes: grail.com/podcast/

Dr. Nima Nabavizadeh, principal investigator for the PATHFINDER 2 study, shares key takeaways from this data. He noted: “As an oncologist, I have seen too many patients diagnosed only after their cancer has spread, when treatment decisions become more difficult. By helping find more cancers earlier, when more treatment options may be available, there is great potential for multi-cancer early detection to transform cancer screening.” Find all of GRAIL’s data from #ASCO26 here: bit.ly/4wY05Ij RX Only. See Important Safety Information: bit.ly/3QHmPWo

PATHFINDER 2 data being presented today at #ASCO26 offer new evidence on the safety and performance of a multi-cancer early detection (MCED) test when used alongside recommended #CancerScreenings. Review the results from the largest #MCED interventional study in North America: bit.ly/3QcmqBe RX Only. See Important Safety Information: bit.ly/3QHmPWo

When Doreen volunteered for the NHS-Galleri trial evaluating a multi-cancer early detection (#MCED) test, she never expected the study would identify a signal for #lymphoma in her own blood. Follow-up testing confirmed a Stage I-II lymphoma diagnosis and Doreen was able to promptly begin treatment. Today, she’s back on her bike and sharing her journey to help others understand the importance of #EarlyCancerDetection. See more about the NHS-Galleri trial: bit.ly/4wY05Ij #ASCO26 The overall sensitivity in study participants with lymphoma was 56.3% (27.3% for stage I, 58.3% stage II, 71.7% stage III, 60.9% stage IV).

Results from the NHS-Galleri trial presented at #ASCO26 found that the addition of the Galleri test to standard-of-care cancer screenings led to a four-fold increase in screen-detected cancers. Learn more about our data from ASCO: bit.ly/4wY05Ij The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. RX Only. See Important Safety Information: bit.ly/3QHmPWo

Today at #ASCO26, we are presenting full results from the NHS-Galleri trial, evaluating annual multi-cancer early detection (MCED) blood testing in more than 142,000 participants across England’s National Health Service (NHS). Review the findings: bit.ly/4uBd80F RX Only. See Important Safety Information: bit.ly/3QHmPWo

Our #ASCO26 program highlights new data across #MCED testing, including detailed results from the NHS-Galleri trial, results from the PATHFINDER 2 study, and implementation insights in a private practice setting. See more: bit.ly/4nZhkF6 #EarlyCancerDetection

Want to stay up to date on all things GRAIL? Sign up for our newsletter to receive updates on the work we’re doing to shape the future of early cancer detection: bit.ly/44j6Jt6 #EarlyCancerDetection #CancerScreening #MCED

Today GRAIL reported first quarter 2026 financial results. Read the press release: bit.ly/4nbY0E8

We will announce first quarter 2026 financial results on May 5. Register for the webcast: bit.ly/4mMtf8w Read more: bit.ly/3OTy9nG

At #ASCO26, we’re presenting primary results from the NHS-Galleri trial, the first randomized controlled study of an #MCED test, plus the full PATHFINDER 2 dataset. Together, this data strengthens evidence on MCED performance, safety, and clinical utility. 📊: bit.ly/42jLIjh

Research has shown that many patients with cancer are diagnosed through an emergency route, and these patients are more likely to have poor survival, even beyond the fact that they are also more likely to be diagnosed at a late stage. Patients diagnosed through more managed routes, such as cancer screening, are more likely to have early-stage disease and higher survival. At #AACR26, join us for a poster presentation exploring cancers first identified in the emergency department and what this route to diagnosis may reveal about patterns in cancer care. #CancerResearch #EarlyCancerDetection

We’re bringing new insights to #AACR26 across early cancer detection, screening behavior, and liquid biopsy research. First, explore GRAIL data on emergency presentation during cancer diagnosis and survival, as well as late-breaking research examining standard screening adherence following a negative multi-cancer early detection (MCED) test. Then, join us for an oral presentation in partnership with AstraZeneca exploring the potential role of ctDNA clearance in treatment monitoring for extensive-stage small cell lung cancer. #CancerScreening #CancerResearch #EarlyCancerDetection

Today we announced a collaboration with EPIC to integrate the Galleri multi-cancer early detection (#MCED) test into EPIC’s electronic health record (EHR) platform, supporting broader adoption across the US #HealthSystems. Read the press release: bit.ly/4t7ZzFd

Most cancer deaths are caused by cancers that don’t have a screening test. Multi-cancer early detection (#MCED) tests can detect signals for several cancers, catching them earlier, when it counts. Learn more: bit.ly/4ag0Sda #EarlyCancerDetection

Seven in 10 cancer deaths in the US are from cancers with no screening recommendations, including pancreatic, liver, ovarian, and more. Learn how multi-cancer early detection (#MCED) testing can help catch cancer earlier: bit.ly/3ZuUutm #EarlyCancerDetection

We recently celebrated 10 years of GRAIL across our sites and with our remote employees, recognizing all the people behind the incredible progress we have made in that time. Thank you to everyone who participated and helped bring this day to life. As we look to the next decade, we carry forward what started GRAIL in the first place: the curiosity to follow an unexpected signal, and the determination to turn possibility into progress – together. #GRAIL #EarlyCancerDetection

Five-year CCGA3 outcomes in @JCOPO_ASCO show that cancers with a cancer signal detected result using a blood-based multi-cancer early detection (#MCED) test had survival consistent with matched SEER populations, including early-stage disease. The MCED test was likely to find clinically significant cancers without contributing to overdiagnosis. Read the abstract: bit.ly/4s5ft2z The Galleri test does not detect a signal for all cancers, and false positive and false negative results can occur. Diagnostic testing is needed to confirm cancer.